

Jeffery M Klco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8599126/publications.pdf>

Version: 2024-02-01

95
papers

12,735
citations

87886

38
h-index

69246

77
g-index

96
all docs

96
docs citations

96
times ranked

17446
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2013, 368, 2059-2074.	27.0	4,139
2	The Origin and Evolution of Mutations in Acute Myeloid Leukemia. <i>Cell</i> , 2012, 150, 264-278.	28.9	1,365
3	Suppression of tumor growth through disruption of hypoxia-inducible transcription. <i>Nature Medicine</i> , 2000, 6, 1335-1340.	30.7	726
4	Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. <i>Cancer Cell</i> , 2002, 1, 237-246.	16.8	695
5	Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. <i>Nature</i> , 2015, 518, 552-555.	27.8	685
6	von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. <i>Human Molecular Genetics</i> , 2001, 10, 1019-1027.	2.9	341
7	Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2014, 25, 379-392.	16.8	330
8	Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2018, 379, 2330-2341.	27.0	322
9	Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 811.	7.4	302
10	Use of Whole-Genome Sequencing to Diagnose a Cryptic Fusion Oncogene. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1577.	7.4	233
11	The genomic landscape of core-binding factor acute myeloid leukemias. <i>Nature Genetics</i> , 2016, 48, 1551-1556.	21.4	215
12	Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 16768-16773.	7.1	211
13	Optimizing Cancer Genome Sequencing and Analysis. <i>Cell Systems</i> , 2015, 1, 210-223.	6.2	174
14	TAK1 restricts spontaneous NLRP3 activation and cell death to control myeloid proliferation. <i>Journal of Experimental Medicine</i> , 2018, 215, 1023-1034.	8.5	167
15	pVHL Modification by NEDD8 Is Required for Fibronectin Matrix Assembly and Suppression of Tumor Development. <i>Molecular and Cellular Biology</i> , 2004, 24, 3251-3261.	2.3	156
16	Essential role for the second extracellular loop in C5a receptor activation. <i>Nature Structural and Molecular Biology</i> , 2005, 12, 320-326.	8.2	147
17	The genomic landscape of pediatric myelodysplastic syndromes. <i>Nature Communications</i> , 2017, 8, 1557.	12.8	143
18	Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. <i>Nature Communications</i> , 2018, 9, 3962.	12.8	142

#	ARTICLE	IF	CITATIONS
19	Genomic impact of transient low-dose decitabine treatment on primary AML cells. <i>Blood</i> , 2013, 121, 1633-1643.	1.4	137
20	C5a Receptor Oligomerization. <i>Journal of Biological Chemistry</i> , 2003, 278, 35345-35353.	3.4	102
21	Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells. <i>Leukemia</i> , 2015, 29, 1279-1289.	7.2	96
22	Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. <i>Blood</i> , 2016, 127, 893-897.	1.4	94
23	Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. <i>Molecular Cancer Research</i> , 2003, 1, 453-62.	3.4	94
24	Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. <i>Lancet Oncology</i> , The, 2020, 21, 551-560.	10.7	92
25	Advances in germline predisposition to acute leukaemias and myeloid neoplasms. <i>Nature Reviews Cancer</i> , 2021, 21, 122-137.	28.4	91
26	Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. <i>Journal of Clinical Investigation</i> , 2011, 121, 1445-1455.	8.2	91
27	Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. <i>Cancer Discovery</i> , 2021, 11, 3008-3027.	9.4	88
28	Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. <i>Blood</i> , 2015, 125, 619-628.	1.4	86
29	Enhancer Hijacking Drives Oncogenic <i>BCL11B</i> Expression in Lineage-Ambiguous Stem Cell Leukemia. <i>Cancer Discovery</i> , 2021, 11, 2846-2867.	9.4	83
30	Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies. <i>Journal of Clinical Investigation</i> , 2017, 127, 3657-3674.	8.2	80
31	Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. <i>JCI Insight</i> , 2018, 3, .	5.0	71
32	Phase Separation Mediates NUP98 Fusion Oncoprotein Leukemic Transformation. <i>Cancer Discovery</i> , 2022, 12, 1152-1169.	9.4	68
33	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. <i>Cancer Cell</i> , 2021, 39, 1519-1530.e4.	16.8	64
34	Mechanistic insights and potential therapeutic approaches for <i>NUP98</i> -rearranged hematologic malignancies. <i>Blood</i> , 2020, 136, 2275-2289.	1.4	58
35	Genetic Analysis of the First and Third Extracellular Loops of the C5a Receptor Reveals an Essential WXFG Motif in the First Loop. <i>Journal of Biological Chemistry</i> , 2006, 281, 12010-12019.	3.4	57
36	A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 735-745.	7.2	56

#	ARTICLE	IF	CITATIONS
37	Donor-derived MDS/AML in families with germline GATA2 mutation. <i>Blood</i> , 2018, 132, 1994-1998.	1.4	48
38	Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. <i>Experimental Hematology</i> , 2016, 44, 603-613.	0.4	44
39	CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells. <i>Nature Communications</i> , 2022, 13, 587.	12.8	41
40	Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study. <i>American Journal of Hematology</i> , 2011, 86, 796-800.	4.1	39
41	Integrated Genomic Analysis Identifies <i>UBTF</i> Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 194-207.	5.0	38
42	Molecular basis of <i>ETV6</i> -mediated predisposition to childhood acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 364-373.	1.4	37
43	Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2072-2081.	1.6	34
44	Bone marrow biopsy in patients with hepatitis C virus infection: Spectrum of findings and diagnostic utility. <i>American Journal of Hematology</i> , 2010, 85, 106-110.	4.1	33
45	Pediatric MDS and bone marrow failure-associated germline mutations in <i>SAMD9</i> and <i>SAMD9L</i> impair multiple pathways in primary hematopoietic cells. <i>Leukemia</i> , 2021, 35, 3232-3244.	7.2	32
46	The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. <i>Nature Communications</i> , 2021, 12, 985.	12.8	31
47	Use of classic and novel immunohistochemical markers in the diagnosis of cutaneous myeloid sarcoma. <i>Journal of Cutaneous Pathology</i> , 2011, 38, 945-953.	1.3	30
48	The <i>RUNX1</i> database (<i>RUNX1db</i>): establishment of an expert curated <i>RUNX1</i> registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. <i>Haematologica</i> , 2021, 106, 3004-3007.	3.5	29
49	Molecular Pathology of Myeloproliferative Neoplasms. <i>American Journal of Clinical Pathology</i> , 2010, 133, 602-615.	0.7	28
50	Notch signaling in acute promyelocytic leukemia. <i>Leukemia</i> , 2013, 27, 1548-1557.	7.2	28
51	Structure of the Complement Factor 5a Receptor-Ligand Complex Studied by Disulfide Trapping and Molecular Modeling. <i>Journal of Biological Chemistry</i> , 2008, 283, 7763-7775.	3.4	25
52	Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse. <i>Nature Cancer</i> , 2021, 2, 819-834.	13.2	24
53	Transcription factor <i>MIST1</i> in terminal differentiation of mouse and human plasma cells. <i>Physiological Genomics</i> , 2011, 43, 174-186.	2.3	23
54	Immunohistochemical Analysis of Monocytic Leukemias. <i>American Journal of Clinical Pathology</i> , 2011, 135, 720-730.	0.7	21

#	ARTICLE	IF	CITATIONS
55	Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators. <i>Blood Cancer Discovery</i> , 2021, 2, 586-599.	5.0	21
56	Rara haploinsufficiency modestly influences the phenotype of acute promyelocytic leukemia in mice. <i>Blood</i> , 2011, 117, 2460-2468.	1.4	17
57	Expression and Function of PML-RARA in the Hematopoietic Progenitor Cells of Ctsg-PML-RARA Mice. <i>PLoS ONE</i> , 2012, 7, e46529.	2.5	15
58	SequncErr: measuring and suppressing sequencer errors in next-generation sequencing data. <i>Genome Biology</i> , 2021, 22, 37.	8.8	15
59	Genetic Heterogeneity of Induced Pluripotent Stem Cells: Results from 24 Clones Derived from a Single C57BL/6 Mouse. <i>PLoS ONE</i> , 2015, 10, e0120585.	2.5	12
60	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 4800-4805.	4.1	12
61	The spectrum of adult B-lymphoid leukemias with BCR-ABL: Molecular diagnostic, cytogenetic, and clinical laboratory perspectives. <i>American Journal of Hematology</i> , 2008, 83, 901-907.	4.1	9
62	Comprehensive discovery of noncoding RNAs in acute myeloid leukemia cell transcriptomes. <i>Experimental Hematology</i> , 2017, 55, 19-33.	0.4	9
63	Clonal dynamics of donor-derived myelodysplastic syndrome after unrelated hematopoietic cell transplantation for high-risk pediatric B-lymphoblastic leukemia. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002980.	1.2	7
64	Rational biomarker development for the early and minimally invasive monitoring of AML. <i>Blood Advances</i> , 2021, 5, 4515-4520.	5.2	6
65	Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation. <i>Leukemia and Lymphoma</i> , 2017, 58, 247-250.	1.3	5
66	DNMT3A R882H Overexpression Leads To Hematopoietic and Skin Alterations In Transgenic Mice. <i>Blood</i> , 2013, 122, 479-479.	1.4	4
67	Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10004-10004.	1.6	3
68	Complement factor 5a receptor chimeras reveal the importance of lipid-facing residues in transport competence. <i>FEBS Journal</i> , 2009, 276, 2786-2800.	4.7	2
69	Comprehensive Genomic Profiling of Pediatric Therapy-Related Myeloid Neoplasms Identifies Mecom Dysregulation to be Associated with Poor Outcome. <i>Blood</i> , 2019, 134, 1394-1394.	1.4	2
70	Enhancer Hijacking of BCL11B Defines a Subtype of Lineage Ambiguous Acute Leukemia. <i>Blood</i> , 2020, 136, LBA-3-LBA-3.	1.4	2
71	Comprehensive Analysis Of HOX Gene Expression and DNA Methylation From 189 Primary AMLs Demonstrates Canonical Patterns Associated With Hematopoietic Stem/Progenitors and Recurrent AML Mutations. <i>Blood</i> , 2013, 122, 2496-2496.	1.4	2
72	Novel V1551L Mutation in SAMD9L Inhibits Cell Cycle Progression and Results in Pancytopenia That Progresses to MDS with Monosomy 7. <i>Blood</i> , 2018, 132, 3863-3863.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Integrative Analysis of Pediatric Acute Leukemia Identifies Immature Subtypes That Span a T Lineage and Myeloid Continuum with Distinct Prognoses. <i>Blood</i> , 2019, 134, 918-918.	1.4	1
74	Functional Early Hematopoietic Progenitor Cells Derived From Mouse Embryonic Stem Cells and Induced Pluripotent Stem Cells. <i>Blood</i> , 2013, 122, 2421-2421.	1.4	1
75	The Genomic Landscape of Pediatric Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 956-956.	1.4	1
76	The Mutational Profile of Pediatric Therapy-Related Myeloid Neoplasms. <i>Blood</i> , 2018, 132, 2775-2775.	1.4	1
77	NUP98-KDM5A Fusion Induces Hematopoietic Cell Proliferation and Alters Myelo-Erythropoietic Differentiation. <i>Blood</i> , 2019, 134, 3775-3775.	1.4	1
78	Activity of venetoclax against relapsed acute undifferentiated leukemia. <i>Cancer</i> , 2021, 127, 2608-2611.	4.1	0
79	Abstract 633: Thiopurines and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse. , 2021, , .		0
80	Abstract 642: Genomes for Kids: Comprehensive DNA and RNA sequencing defining the scope of actionable mutations in pediatric cancer. , 2021, , .		0
81	Poster: ALL-144: Oncogenic Deregulation of BCL11B in Lineage Ambiguous Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S207.	0.4	0
82	Dimerization/oligomerization in G proteinâ€coupled receptors (GPCRs) involve the participation of all transmembrane domains. <i>FASEB Journal</i> , 2007, 21, A613.	0.5	0
83	Activation of Notch Signaling Is An Early Event in the Development of PML-Rara-Induced Acute Promyelocytic Leukemia (APL). <i>Blood</i> , 2011, 118, 2468-2468.	1.4	0
84	Functional Hematopoietic Cells Derived From Mouse Embryonic Stem Cells.. <i>Blood</i> , 2012, 120, 2304-2304.	1.4	0
85	Deep Digital Sequencing Identifies an AML Subclone with Enhanced in Vitro and in Vivo Growth Properties Associated with Disease Relapse. <i>Blood</i> , 2012, 120, 407-407.	1.4	0
86	In Vitro Decitabine Treatment Demonstrates Heterogeneous Changes in Methylation and Gene Expression in Primary AML Samples.. <i>Blood</i> , 2012, 120, 2527-2527.	1.4	0
87	Subclonal â€skewingâ€Of De Novo AML Samples After Engraftment In Immunodeficient Mice. <i>Blood</i> , 2013, 122, 609-609.	1.4	0
88	Enforced Differentiation of Dnmt3a-Null Bone Marrow Leads to Failure with c-Kit Mutations Driving Leukemic Transformation. <i>Blood</i> , 2014, 124, 837-837.	1.4	0
89	DNMT3A R882H Can Cooperate with FLT3-ITD to Cause AML in Mice. <i>Blood</i> , 2015, 126, 2458-2458.	1.4	0
90	Reprogramming of Leukemic and Pre-Leukemic Cells from Primary Human De Novo Acute Myeloid Leukemia Samples into Induced Pluripotent Stem (iPS) Cells. <i>Blood</i> , 2015, 126, 1862-1862.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Non-Malignant Oligoclonal Hematopoiesis Commonly Follows Cytoreductive Chemotherapy in Adult De Novo AML Patients. <i>Blood</i> , 2015, 126, 686-686.	1.4	0
92	Hematolymphoid System. <i>Molecular Pathology Library</i> , 2018, , 89-136.	0.1	0
93	Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB. <i>Blood</i> , 2018, 132, 5241-5241.	1.4	0
94	Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 178-178.	1.4	0
95	Integrated Genomic Analysis Identifies UBTF Tandem Duplications As a Subtype-Defining Lesion in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, LBA-4-LBA-4.	1.4	0